PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.
Stem cell treatment research shows promise in reversing hair loss in mice, but it's likely 10 years away and expensive. Current recommended treatments include minoxidil, finasteride, and hair transplants.
Oral Dutasteride and topical Finasteride may have similar effects on scalp DHT, but topical Dutasteride might be less effective due to poor absorption. Combining oral Dutasteride with topical Finasteride could potentially enhance results by blocking DHT in both the scalp and serum.
The user has been using a combination spray of finasteride, minoxidil, and tretinoin for 5 months, along with microneedling and biotin, and is uncertain about hair regrowth progress. Other users suggest more time is needed for results, with peak results at 2 years, and mention oral dutasteride as an effective treatment.
PP405, a potential treatment for male pattern baldness, shows promise with some participants experiencing hair regrowth in early trials. However, it is not yet considered a cure and may be used alongside existing treatments like minoxidil and finasteride.
PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.
A user shared their positive experience with finasteride and minoxidil for hair regrowth, reporting no side effects and recommending early treatment for hair loss. Others discussed their experiences, side effects, and questions about dosages and application methods.
GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.
The user experienced significant hair regrowth using 1mg of finasteride three times a week, with mild side effects like gynecomastia and breakouts. They are considering starting minoxidil.
PP405 may reactivate dormant hair follicles but won't replace hair transplants or resurrect dead follicles. Its effectiveness, cost, and impact compared to treatments like minoxidil and finasteride are uncertain.
Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.
PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.
PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.
The conversation discusses hair loss treatments, specifically the use of oral finasteride and topical minoxidil, with the user sharing their two-year progress and routine. The user experienced initial shedding but saw improvements after six months, and they recently started taking dutasteride.
PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.
Finasteride is preferred over dutasteride due to its longer history, more research, and FDA approval, despite dutasteride being more potent. Users report varied side effects, influencing personal treatment choices.
A 24-year-old male doctor shares his 3-month progress using 0.5 mg oral finasteride and 5% topical minoxidil daily, noting some hair regrowth and incorporating microneedling. He prefers a "less is more" approach initially and discusses the potential benefits of oral minoxidil.
A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.
Pyrilutamide's long-term stability is uncertain, with potential degradation after 8-9 months if not stored properly. It's recommended to use fresh batches and store them in a cool, dark place.
The conversation discusses hair shedding after starting a treatment regimen including topical dutasteride, RU58841, minoxidil, and keto shampoo. Shedding is considered normal, and users suggest adjustments like increasing dutasteride dosage or using oral medications for better results.
Dutasteride is favored over finasteride by some for better hair loss reversal, improved skin, and fewer side effects, though individual responses vary. It may also help with dandruff and eczema but has a slightly higher risk of gynecomastia.
Finasteride is being used to prevent further hair loss, with hopes of thickening existing thin hair, but results are slow. Users suggest adding minoxidil, dermastamping, and possibly dutasteride for better results.
A 33-year-old male shares his successful hair regrowth journey using oral finasteride (1.25 mg daily) for 22 months and topical minoxidil for 10 years, along with dermarolling. He reports significant hair regrowth, no side effects, and emphasizes the importance of consistency in his routine.
The user stopped taking finasteride due to erectile dysfunction, which they later realized was caused by excessive porn use and not the medication. They resumed finasteride, added dutasteride, and are using minoxidil and microneedling to regain hair.
RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.
Low-dose topical finasteride may reduce scalp DHT with fewer side effects than oral finasteride, though it can still lower blood serum DHT. Users report varying experiences, with some finding topical use effective and side-effect-free, while others note significant DHT suppression.
Combining therapies like scyllo-inositol, alpha-ketoglutarate, and autophagy-inducing supplements may enhance hair growth and prevent hair loss. Reporting individual results can accelerate progress in hair loss treatments.
A sugar gel was claimed to trigger hair regrowth, but users reported no results and potential cancer risks. The discussion included comparisons to minoxidil and skepticism about the effectiveness of the sugar treatment.
The user stopped finasteride due to testicular aches and switched to minoxidil, seeing positive results in three months. They are considering topical finasteride but are cautious because of past side effects from oral use.